AP2227A - 5,7-diaminopyrazolo [4,3-d]pyrimidines with PDE-5 inhibiting activity. - Google Patents
5,7-diaminopyrazolo [4,3-d]pyrimidines with PDE-5 inhibiting activity.Info
- Publication number
- AP2227A AP2227A AP2006003591A AP2006003591A AP2227A AP 2227 A AP2227 A AP 2227A AP 2006003591 A AP2006003591 A AP 2006003591A AP 2006003591 A AP2006003591 A AP 2006003591A AP 2227 A AP2227 A AP 2227A
- Authority
- AP
- ARIPO
- Prior art keywords
- diaminopyrazolo
- pde
- pyrimidines
- inhibiting activity
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0327319.0A GB0327319D0 (en) | 2003-11-24 | 2003-11-24 | Novel pharmaceuticals |
| PCT/IB2004/003747 WO2005049616A1 (en) | 2003-11-24 | 2004-11-12 | 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2006003591A0 AP2006003591A0 (en) | 2006-04-30 |
| AP2227A true AP2227A (en) | 2011-03-29 |
Family
ID=29764364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2006003591A AP2227A (en) | 2003-11-24 | 2004-11-12 | 5,7-diaminopyrazolo [4,3-d]pyrimidines with PDE-5 inhibiting activity. |
Country Status (44)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1804799B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| BRPI0515483A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase |
| JP5043668B2 (ja) | 2004-09-20 | 2012-10-10 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
| MX2007003332A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
| MX2007003327A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. |
| TW200626154A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
| JP5149009B2 (ja) | 2004-09-20 | 2013-02-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体 |
| EP1809632A2 (en) * | 2004-10-28 | 2007-07-25 | Pharmacia & Upjohn Company LLC | Pyrazolo[4,3-d]pyrimidine derivatives useful as pde-5 inhibitors |
| AU2006245416B2 (en) * | 2005-05-12 | 2012-02-23 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
| MX2007015216A (es) | 2005-06-03 | 2008-02-22 | Xenon Pharmaceuticals Inc | Derivados de aminotiazol y sus usos como agentes terapeuticos. |
| NL1029244C2 (nl) * | 2005-06-10 | 2006-12-12 | Ronald Silfried Marlin | Middel ter vergroting van het mannelijk geslachtsorgaan. |
| DE102005050377A1 (de) * | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
| NL2000291C2 (nl) | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
| CA2633035C (en) | 2005-12-15 | 2016-05-10 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
| EP1820502A1 (en) * | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising azolylcarbinol compounds |
| WO2007113243A2 (en) * | 2006-03-31 | 2007-10-11 | Investigación Y Clínica Andrológicas S.L. | Use of pde 5 inhibitors for the treatment of overactive bladder |
| WO2008132589A1 (en) * | 2007-05-01 | 2008-11-06 | Pfizer Limited | Combinations comprising pregabalin |
| WO2009050554A2 (en) * | 2007-10-19 | 2009-04-23 | Pfizer Inc. | Treatment of central nervous system disorders |
| DE102008063992A1 (de) * | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
| ES2602794T3 (es) | 2011-03-31 | 2017-02-22 | Pfizer Inc | Piridinonas bicíclicas novedosas |
| WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
| JP6043355B2 (ja) | 2011-08-31 | 2016-12-14 | ファイザー・インク | ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| WO2013164730A1 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2. |
| WO2014045162A1 (en) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| EP2931731A1 (en) | 2012-12-11 | 2015-10-21 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
| CA2893333C (en) | 2012-12-19 | 2017-10-24 | Pfizer Inc. | Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| JP2016507551A (ja) | 2013-02-13 | 2016-03-10 | ファイザー・インク | ヘテロアリール置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| BR112015019276A2 (pt) | 2013-02-19 | 2017-07-18 | Pfizer | compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios |
| ES2742078T3 (es) | 2013-10-04 | 2020-02-13 | Pfizer | Piridonas bicíclicas novedosas como moduladores de gamma-secretasa |
| CN106029647A (zh) * | 2013-12-20 | 2016-10-12 | 拜耳制药股份公司 | 葡萄糖转运抑制剂 |
| MX369074B (es) | 2014-04-01 | 2019-10-28 | Pfizer | Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de la gamma secretasa. |
| UA119166C2 (uk) * | 2014-04-04 | 2019-05-10 | Х. Луннбек А/С | Галогеновані хіназолін-thf-аміни як інгібітори pde1 |
| MD20160105A2 (ro) | 2014-04-10 | 2017-03-31 | Pfizer Inc. | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide |
| JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
| ES2733502T3 (es) | 2014-08-06 | 2019-11-29 | Pfizer | Compuestos de imidazopiridazina |
| WO2016091774A1 (en) * | 2014-12-08 | 2016-06-16 | Janssen Sciences Ireland Uc | Piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv) |
| PE20171318A1 (es) | 2015-02-03 | 2017-09-07 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas |
| EP3766885B1 (en) | 2015-06-17 | 2022-05-25 | Pfizer Inc. | Tricyclic compounds and their use as phosphodiesterase inhibitors |
| JP2018534251A (ja) | 2015-09-24 | 2018-11-22 | ファイザー・インク | Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド |
| AU2016325665A1 (en) | 2015-09-24 | 2018-03-08 | Pfizer Inc. | N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides |
| JP2018531924A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用 |
| CN108699080B (zh) | 2016-02-23 | 2021-05-14 | 辉瑞公司 | 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物 |
| DK3478679T3 (da) | 2016-07-01 | 2021-06-21 | Pfizer | 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme |
| FI3642202T3 (fi) | 2017-06-22 | 2023-03-01 | Dihydro-pyrrolo-pyridiinijohdannaisia | |
| DK3768669T3 (da) | 2018-03-23 | 2023-04-24 | Pfizer | Piperazinazaspiroderivater |
| AU2019282098B2 (en) | 2018-06-04 | 2023-12-14 | Evotec International Gmbh | Pyrazolopyrimidine compounds as adenosine receptor antagonists |
| TWI837169B (zh) * | 2018-08-24 | 2024-04-01 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| WO2024118524A1 (en) | 2022-11-28 | 2024-06-06 | Cerevel Therapeutics, Llc | Azaindole compounds and their use as phosphodiesterase inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000024745A1 (en) * | 1998-10-23 | 2000-05-04 | Pfizer Limited | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
| WO2002000600A1 (de) * | 2000-06-27 | 2002-01-03 | Qiagen Gmbh | Verwendung von kompositionen aus kationischen verbindungen und protonendonoren zur stabilisierung und/oder isolierung von nukleinsäuren in bzw. aus mikroorganismen - wie prokaryonten, pilzen, protozoen oder algen |
| WO2004096810A1 (en) * | 2003-04-29 | 2004-11-11 | Pfizer Limited | 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW444018B (en) * | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
| GB9823102D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
| DE10031584A1 (de) * | 2000-06-29 | 2002-01-10 | Merck Patent Gmbh | 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine |
| DE60237425D1 (de) * | 2002-03-28 | 2010-10-07 | Univerzita Palackeho V Olomouc | PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung |
-
2003
- 2003-11-24 GB GBGB0327319.0A patent/GB0327319D0/en not_active Ceased
-
2004
- 2004-11-12 KR KR1020087009034A patent/KR100893999B1/ko not_active IP Right Cessation
- 2004-11-12 CN CN2004800345707A patent/CN1882591B/zh not_active Expired - Fee Related
- 2004-11-12 AP AP2006003591A patent/AP2227A/xx active
- 2004-11-12 EP EP04798876A patent/EP1689751B1/en active Active
- 2004-11-12 PL PL04798876T patent/PL1689751T3/pl unknown
- 2004-11-12 CN CN200910151866A patent/CN101647802A/zh active Pending
- 2004-11-12 JP JP2006540647A patent/JP4056015B2/ja not_active Expired - Fee Related
- 2004-11-12 MX MXPA06005914A patent/MXPA06005914A/es active IP Right Grant
- 2004-11-12 CN CN200810085940XA patent/CN101362765B/zh not_active Expired - Fee Related
- 2004-11-12 RS RSP-2010/0534A patent/RS51556B/en unknown
- 2004-11-12 CA CA002546987A patent/CA2546987C/en not_active Expired - Fee Related
- 2004-11-12 DE DE602004029705T patent/DE602004029705D1/de active Active
- 2004-11-12 AU AU2004290643A patent/AU2004290643B2/en not_active Ceased
- 2004-11-12 PT PT04798876T patent/PT1689751E/pt unknown
- 2004-11-12 EA EA200600677A patent/EA011772B1/ru not_active IP Right Cessation
- 2004-11-12 WO PCT/IB2004/003747 patent/WO2005049616A1/en active Application Filing
- 2004-11-12 DK DK04798876.1T patent/DK1689751T3/da active
- 2004-11-12 ES ES04798876T patent/ES2351622T3/es active Active
- 2004-11-12 ME MEP-2010-203A patent/ME01216B/me unknown
- 2004-11-12 GE GEAP20049412A patent/GEP20084528B/en unknown
- 2004-11-12 OA OA1200600166A patent/OA13289A/en unknown
- 2004-11-12 NZ NZ548097A patent/NZ548097A/en not_active IP Right Cessation
- 2004-11-12 SG SG200704860-6A patent/SG133614A1/en unknown
- 2004-11-12 AT AT04798876T patent/ATE485297T1/de active
- 2004-11-12 CN CN2008100859397A patent/CN101362764B/zh not_active Expired - Fee Related
- 2004-11-12 BR BRPI0416869-0A patent/BRPI0416869A/pt not_active Application Discontinuation
- 2004-11-12 SI SI200431562T patent/SI1689751T1/sl unknown
- 2004-11-12 KR KR1020067010152A patent/KR100848216B1/ko not_active IP Right Cessation
- 2004-11-22 UY UY28625A patent/UY28625A1/es active IP Right Grant
- 2004-11-22 MY MYPI20044834A patent/MY140872A/en unknown
- 2004-11-22 PE PE2004001138A patent/PE20051061A1/es not_active Application Discontinuation
- 2004-11-23 NL NL1027568A patent/NL1027568C2/nl not_active IP Right Cessation
- 2004-11-23 PA PA20048617701A patent/PA8617701A1/es unknown
- 2004-11-23 TW TW093136019A patent/TWI265031B/zh not_active IP Right Cessation
- 2004-11-23 AR ARP040104331A patent/AR046711A1/es not_active Application Discontinuation
- 2004-12-11 UA UAA200605669A patent/UA81994C2/uk unknown
-
2006
- 2006-04-10 IS IS8406A patent/IS8406A/is unknown
- 2006-04-10 ZA ZA200602899A patent/ZA200602899B/en unknown
- 2006-05-04 IL IL175433A patent/IL175433A/en not_active IP Right Cessation
- 2006-05-23 EC EC2006006580A patent/ECSP066580A/es unknown
- 2006-05-23 CR CR8416A patent/CR8416A/es unknown
- 2006-05-24 TN TNP2006000154A patent/TNSN06154A1/fr unknown
- 2006-05-24 MA MA29050A patent/MA28172A1/fr unknown
- 2006-06-23 NO NO20062950A patent/NO336526B1/no not_active IP Right Cessation
-
2007
- 2007-05-22 HK HK07105414.0A patent/HK1099286A1/xx not_active IP Right Cessation
-
2009
- 2009-08-03 HK HK09107080.7A patent/HK1128917A1/xx not_active IP Right Cessation
-
2010
- 2010-11-24 CY CY20101101062T patent/CY1110933T1/el unknown
- 2010-11-26 HR HR20100651T patent/HRP20100651T1/hr unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000024745A1 (en) * | 1998-10-23 | 2000-05-04 | Pfizer Limited | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
| WO2002000600A1 (de) * | 2000-06-27 | 2002-01-03 | Qiagen Gmbh | Verwendung von kompositionen aus kationischen verbindungen und protonendonoren zur stabilisierung und/oder isolierung von nukleinsäuren in bzw. aus mikroorganismen - wie prokaryonten, pilzen, protozoen oder algen |
| WO2004096810A1 (en) * | 2003-04-29 | 2004-11-11 | Pfizer Limited | 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2227A (en) | 5,7-diaminopyrazolo [4,3-d]pyrimidines with PDE-5 inhibiting activity. | |
| IL182099A0 (en) | Piperidinylamino-thieno[2,3-d] pyrimidine compounds | |
| EP1599482A4 (en) | PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES | |
| NO20040540L (no) | 4-amino-6-fenylpyrrolo[2,3-D]pyrimidinderivater. | |
| HK1086012A1 (en) | 8-substitued-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives | |
| AP2005003403A0 (en) | Substituted pyrimidinones. | |
| ZA200304090B (en) | Agricultural articles. | |
| PL376916A1 (pl) | Pochodne pirymido [4,5-d] pirymidyny o działaniu przeciwrakowym | |
| HK1088893A1 (en) | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives | |
| AP2005003365A0 (en) | Hiv inhibiting 1, 2, 4-triazines. | |
| ZA200501679B (en) | Recreation range. | |
| MXPA03007320A (es) | Nuevos compuestos de pirimidina. | |
| PL358551A1 (en) | 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines | |
| AP2006003497A0 (en) | 2-Substituted pyrimidines. | |
| AP2006003539A0 (en) | 5-halogeno-[1,2,4]triazolo[1,5-A] pyrimidines for combating animal pests. | |
| MXPA03004498A (es) | Uso de pirazolo (4,3-d)pirimidinas. | |
| TWI372760B (en) | A pyrazolo[1,5-a]pyrimidine compound | |
| MXPA03004907A (es) | Uso de pirazolo (4,3-d) pirimidinas. | |
| GB0323137D0 (en) | 2,4,6- Trisubstituted pyrimidines and their different uses | |
| AP2006003496A0 (en) | 2-Substituted pyrimidines. | |
| PL361915A1 (en) | Substituted 3.4-dihydro-pyrido[1,2-a]pyrimidines | |
| IL173347A0 (en) | 7-SUBSTITUTED 3-NITRO-PYRAZOLO[1,5-a] PYRIMIDINES | |
| TJ431B (en) | 2-Brom-7-methil-5-oxo-5h-1,3,4-thyodyazol-(3,2-a)pyrimidin, has antibacterial activity | |
| GB0218515D0 (en) | S.d.s. | |
| TJ403B (en) | Dibaferrol, having antimicrobe activity. |